[Retracted] Genipin inhibits the growth of human bladder cancer cells via inactivation of PI3K/Akt signaling
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that, regarding the antibody that had been used to probe for p21 protein in the western blot experiments shown in Fig. 2 (cat. no. sc‑136020, purchased from Santa Cruz Biotechnology, Inc.), this antibody may have been selected inappropriately, since apparently this antibody is specific for a different protein, sometimes referred to as p21‑ARC, which is associated with the actin cytoskeleton. Furthermore, an independent analysis of the data in this paper performed by the Editorial Office revealed that certain of the flow cytometric data featured in Fig. 3A on p. 2623 were strikingly similar to data that had already been published in an article written by a different research group at different research institutes in the journal BMC Cancer. Given that the contentious data named above had already been published prior to the receipt of this paper at Oncology Letters, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Letters 15: 2619-2624, 2018; DOI: 10.3892/ol.2017.7588]
Authors
- Tianbiao Zhang (ORCID: https://orcid.org/0009-0003-9105-1080)
- Donghui Jia (ORCID: https://orcid.org/0000-0003-2325-9747)
- Chaoliang Wang (ORCID: https://orcid.org/0009-0004-1563-0774)
- Xiao-Ming Yang (ORCID: https://orcid.org/0000-0003-3629-0946)
- Ao-Zheng Gu
- Wen-Qi Sun
- Zheng Li
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Oncology Letters
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3892/ol.2026.15949
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00